MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress
September 16, 2021 02:45 ET | MacroGenics, Inc.
Metastatic castration-resistant prostate cancer (mCRPC): 21 of 39 patients (54%) achieved ≥ 50% prostate-specific antigen (PSA) reduction; 10 of 16 (63%) RECIST-evaluable patients had anti-tumor...
MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021
September 16, 2021 02:45 ET | MacroGenics, Inc.
21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary for trial; enrollment proceeding to Part 2 of Cohort A78% of patients had tumor...
MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress
September 12, 2021 19:00 ET | MacroGenics, Inc.
ROCKVILLE, MD, Sept. 12, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA™ in Patients with HER2-Positive Metastatic Breast Cancer
September 07, 2021 16:30 ET | MacroGenics, Inc.
Final overall survival (OS) analysis did not demonstrate a statistically significant advantage for MARGENZA over trastuzumabOS was greater with MARGENZA plus chemotherapy in exploratory subgroups of...
researchdrivelogo.jpg
Global Fetal Bovine Serum Market to Perceive Momentous Growth Due to Growing Demand for Fetal Bovine Serum in Biopharmaceutical Centers – Exclusive Report [199 Pages] By Research Dive
September 06, 2021 09:00 ET | Research Dive
New York, USA, Sept. 06, 2021 (GLOBE NEWSWIRE) -- A new report on the global fetal bovine serum market has been added by Research Dive to its repository. As per the report, the market is expected to...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conferences
September 02, 2021 16:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Sept. 02, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
Rentschler Biopharma logo from PR.jpg
Rentschler Biopharma breaks ground at new U.S. production site in greater Boston
August 12, 2021 08:00 ET | Rentschler Biopharma SE
New facility, adjacent to existing Milford, MA site, to significantly expand cGMP manufacturing capacity, accelerating clinical and commercial supply of essential biopharmaceuticalsSite will employ...
lexaria.jpg
Lexaria Bioscience Corp. (NASDAQ: LEXX) Leads the Way in Innovating Hypertension Treatment
August 04, 2021 08:30 ET | Lexaria Bioscience Corp.
NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Date of Second Quarter 2021 Financial Results Conference Call
July 22, 2021 16:05 ET | MacroGenics, Inc.
ROCKVILLE, MD, July 22, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
June 16, 2021 07:30 ET | MacroGenics, Inc.
Zai Lab granted combination of regional Asian and global rights for up to four CD3- or CD47-based bispecific moleculesMacroGenics provides rights to Zai Lab for its DART® and TRIDENT® multi-specific...